SOLA Biosciences was founded in 2016 by Dr. Keizo Koya, CEO and Dr. Akinori Hishiya, CSO. Dr. Koya is a serial entrepreneur having experience in founding Strategia (which was acquired by JSI InnoMed). Dr. Hishiya has experience as a researcher at Eli Lilly, the National Center for Geriatrics and Gerontology, Georgia Medical College, Boston Biomedical Research Institute, and Strategia, Inc.

SOLA owns the JUMP70 platform, a gene therapy that uses AAV to express JUMP70, a fusion protein capable of bringing disease-causing proteins into close proximity with the HSP70 protein, so that HSP could refold or induce degradation of the mis-folded aggregate protein which is a cause of neurodegenerative diseases. The lead pipeline, SOL-257, is being developed for ALS, a disease caused by the aggregation of TDP-43 protein.

Introduction of scientific advisers in the US or in AAV field, support capital raising, business development, and IP strategy, etc.